Clinical Trials
3 trialsNCT07536815 2026-04-27
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
CytoDyn, Inc.
Available
NCT03838367 2025-09-09
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
CytoDyn, Inc.
Phase 1/2 Terminated
NCT04313075 2025-07-15
A Compassionate Use Study of Leronlimab in Breast Cancer
CytoDyn, Inc.
No longer available